Search

Your search keyword '"Catapano AL"' showing total 753 results

Search Constraints

Start Over You searched for: Author "Catapano AL" Remove constraint Author: "Catapano AL"
753 results on '"Catapano AL"'

Search Results

1. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

2. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3

3. Adherence to lipid-lowering treatment: the patient perspective

4. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

5. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

6. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

8. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

9. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

10. From novel discovery tools and biomarkers to precision medicine-basic cardiovascular science highlights of 2021/22

13. Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019

14. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

15. 2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019)

16. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

17. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study

18. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

19. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium

20. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

21. Reducing the clinical and public health Burden of Familial hypercholesterolemia

24. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

25. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

26. Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation

27. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up

28. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease

29. 2016 European Guidelines on the Prevention of Cardiovascular Diseases in Clinical Practice Sixth Joint Task Force of the European Society of Cardiology and other Societies on the Prevention of Cardiovascular Diseases in Clinical Practice (consisting of representatives of 10 companies and invited experts) drafted with the extraordinary contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR)

30. Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort

31. Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort

33. European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease

34. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR)

35. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

36. Nuove terapie ipolipemizzanti per i pazienti con ipercolesterolemia familiare. Position paper della Società Italiana per lo studio dell'Arteriosclerosi

37. Moderate alcohol use and health: A consensus paper

38. Clinical, molecular and functional characterization of two novel mutations associated to compound heterozygous FHBL

39. Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy

40. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

41. A simple informative intervention in primary care increases statin adherence

42. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

43. ESC/EAS Guidelines for the management of dyslipidaemias

44. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

45. ESC/EAS Guidelines for the management of dyslipidaemias (vol 32, pg 1769, 2011)

46. Il rischio residuo nelle dislipidemie: ruolo delle lipoproteine ad alta densità e dei trigliceridi plasmatici

Catalog

Books, media, physical & digital resources